Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.
A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
But more detail is awaited, especially on toxicity.
First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.
The Maestra-2 trial will test INCB123667 in platinum-resistant ovarian cancer.
